Results 1 to 10 of about 29,074 (242)

Codon deoptimization of multispecific biologics reduces mispairing during transient mammalian protein expression [PDF]

Frontiers in Bioengineering and Biotechnology
IntroductionCodon optimization is utilized in biologics design to maximize protein expression. Selecting the host organism’s most frequently used codons for each amino acid can significantly enhance recombinant protein expression yields.
Timothy Z. Chang, Weijun Ma, Jane Guo, Jiali Hu, Kalie Mix, Yi Tang, Karen Wong, Eva Bric-Furlong, Amanda Lennon, Brian Hall, Dietmar Hoffmann   +10 more
doaj   +2 more sources

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method

mAbs, 2023
A challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life in vivo is the efficiency of pH-dependent binding ...
Thomas Müller, Carolin Tasser, Michael Tesar, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, Kristina Ellwanger   +6 more
doaj   +1 more source

Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics

Frontiers in Drug Discovery, 2023
Mesothelin is a glypiated, cell-surface glycoprotein expressed at low levels on normal mesothelium but overexpressed by many cancers. Implicated in cell adhesion and multiple signaling pathways, mesothelin’s precise biological function and overall ...
Ida Lin, Peter B. Rupert, Kristina Pilat, Raymond O. Ruff, Della J. Friend, Man Kid Chan, Midori Clarke, Benjamin G. Hoffstrom, Jane Carter, Soheil Meshinchi, Ashok D. Bandaranayake, Christopher Mehlin, James M. Olson, Roland K. Strong, Colin E. Correnti   +14 more
doaj   +1 more source

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

Frontiers in Immunology, 2023
BackgroundSerum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments ...
Ralph Adams, Callum Joyce, Mikhail Kuravskiy, Katriona Harrison, Katriona Harrison, Zainab Ahdash, Matthew Balmforth, Kelda Chia, Cinzia Marceddu, Matthew Coates, James Snowden, Emmanuel Goursaud, Karelle Ménochet, Jean van den Elsen, Richard J. Payne, Richard J. Payne, Alastair D. G. Lawson, Anthony Scott-Tucker, Alex Macpherson   +18 more
doaj   +1 more source

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Drugs in Context, 2021
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success ...
Omar Castaneda-Puglianini, Julio C Chavez   +1 more
doaj   +1 more source

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Biomolecules, 2020
Ligand-targeted toxins (LTTs) are bioengineered molecules which are composed of a targeting component linked to a toxin that induces cell death once the LTT binds its target. Bispecific targeting allows for the simultaneous targeting of two receptors. In
Felix Oh, Jaime F. Modiano, Veronika Bachanova, Daniel A. Vallera   +3 more
doaj   +1 more source

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Cell Reports, 2021
Summary: The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19.
Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, Zhiwei Wu   +13 more
doaj   +1 more source

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

Pharmaceuticals, 2021
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit ...
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino, Giuseppe Curigliano   +5 more
doaj   +1 more source

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Frontiers in Oncology, 2023
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody
David A. Russler-Germain, David A. Russler-Germain, Armin Ghobadi, Armin Ghobadi   +3 more
doaj   +1 more source